microscopy and Dr. Robert White for constructive comments. The Pax3 monoclonal antibody, developed by C.P. Ordahl, was obtained from the Developmental Studies Hybridoma Bank developed under the auspices of the NICHD and maintained by the University of Iowa, Department of Biological Sciences, Iowa City, IA 52242. References 1. Barber TD, Barber MC, Cloutier TE, Friedman TB (1999) PAX3 gene structure, alternative splicing and evolution. Gene 237: 311–319. 2. Barr FG, Fitzgerald JC, Ginsberg JP, Vanella ML, Davis RJ, et al. (1999) Predominant expression of alternative PAX3 and PAX7 forms in myogenic and neural tumor cell lines. Cancer Res 59: 5443–5448. 3. Galibert MD, Yavuzer U, Dexter TJ, Goding CR (1999) Pax3 and regulation of the melanocyte-specific tyrosinase-related protein-1 promoter. J Biol Chem 274: 26894–26900. 4. Muratovska A, Zhou C, He S, Goodyer P, Eccles MR (2003) Paired-Box genes are frequently expressed in cancer and often required for cancer cell survival. Oncogene 22: 7989–7997. 5. Plummer RS, Shea CR, Nelson M, Powell SK, Freeman DM, et al. (2008) PAX3 expression in primary melanomas and nevi. Mod Pathol 21: 525–530. 6. Scholl FA, Kamarashev J, Murmann OV, Geertsen R, Dummer R, et al. (2001) PAX3 is expressed in human melanomas and contributes to tumor cell survival. Cancer Res 61: 823–826. 7. Koyanagi K, Kuo C, Nakagawa T, Mori T, Ueno H, et al. (2005) Multimarker quantitative real-time PCR detection of circulating melanoma cells in peripheral blood: relation to disease stage in melanoma patients. Clin Chem 51: 981–988. 8. Takeuchi H, Morton DL, Kuo C, Turner RR, Elashoff D, et al. (2004) Prognostic significance of molecular upstaging of paraffin-embedded sentinel lymph nodes in melanoma patients. J Clin Oncol 22: 2671–2680. 9. Himoudi N, Nabarro S, Yan M, Gilmour K, Thrasher AJ, et al. (2007) Development of anti-PAX3 immune responses; a target for cancer immuno- therapy. Cancer Immunol Immunother 56: 1381–1395. 10. Matsuzaki Y, Hashimoto S, Fujita T, Suzuki T, Sakurai T, et al. (2005) Systematic identification of human melanoma antigens using serial analysis of gene expression (SAGE). J Immunother 28: 10–19. 11. Rodeberg DA, Nuss RA, Elsawa SF, Erskine CL, Celis E (2006) Generation of tumoricidal PAX3 peptide antigen specific cytotoxic T lymphocytes. Int J Cancer 119: 126–132. 12. Blake JA, Thomas M, Thompson JA, White R, Ziman M (2008) Perplexing Pax: from puzzle to paradigm. Dev Dyn 237: 2791–2803. 13. Chi N, Epstein JA (2002) Getting your Pax straight: Pax proteins in development and disease. Trends Genet 18: 41–47. 14. Frost V, Grocott T, Eccles MR, Chantry A (2008) Self-regulated Pax gene expression and modulation by the TGFbeta superfamily. Crit Rev Biochem Mol Biol 43: 371–391. 15. Lang D, Powell SK, Plummer RS, Young KP, Ruggeri BA (2007) PAX genes: roles in development, pathophysiology, and cancer. Biochem Pharmacol 73: 1–14. 16. Robson EJ, He SJ, Eccles MR (2006) A PANorama of PAX genes in cancer and development. Nat Rev Cancer 6: 52–62. 17. Wang Q, Fang WH, Krupinski J, Kumar S, Slevin M, et al. (2008) Pax genes in embryogenesis and oncogenesis. J Cell Mol Med 12: 2281–2294. 18. Ziman M, White R (2006) PAX genes in cell differentiation, lineage development and pathogenesis. In: Sherbet GV, ed. The Molecular and Cellular Pathology of Cancer Progression and Prognosis. Kerala: Research Signpost. pp 235–259. 19. Medic S, Ziman M (2009) PAX3 across the spectrum: from melanoblast to melanoma. Crit Rev Biochem Mol Biol. pp 1–13. 20. Bang AG, Papalopulu N, Kintner C, Goulding MD (1997) Expression of Pax-3 is initiated in the early neural plate by posteriorizing signals produced by the organizer and by posterior non-axial mesoderm. Development 124: 2075–2085. 21. Blake JA, Ziman MR (2005) Pax3 transcripts in melanoblast development. Dev Growth Differ 47: 627–635. 22. Gershon TR, Oppenheimer O, Chin SS, Gerald WL (2005) Temporally regulated neural crest transcription factors distinguish neuroectodermal tumors of varying malignancy and differentiation. Neoplasia 7: 575–584. 23. Goulding MD, Chalepakis G, Deutsch U, Erselius JR, Gruss P (1991) Pax-3, a novel murine DNA binding protein expressed during early neurogenesis. Embo J 10: 1135–1147. 24. Meulemans D, Bronner-Fraser M (2004) Gene-regulatory interactions in neural crest evolution and development. Dev Cell 7: 291–299. 25. Hornyak TJ, Hayes DJ, Chiu LY, Ziff EB (2001) Transcription factors in melanocyte development: distinct roles for Pax-3 and Mitf. Mech Dev 101: 47–59. 26. Lang D, Lu MM, Huang L, Engleka KA, Zhang M, et al. (2005) Pax3 functions at a nodal point in melanocyte stem cell differentiation. Nature 433: 884–887. 27. He S, Yoon HS, Suh BJ, Eccles MR (2010) PAX3 Is Extensively Expressed in Benign and Malignant Tissues of the Melanocytic Lineage in Humans. J Invest Dermatol. 28. Yang G, Li Y, Nishimura EK, Xin H, Zhou A, et al. (2008) Inhibition of PAX3 by TGF-beta modulates melanocyte viability. Mol Cell 32: 554–563. PAX3 in Melanocytes Author Contributions Conceived and designed the experiments: SM MZ. Performed the experiments: SM. Analyzed the data: SM MZ. Contributed reagents/ materials/analysis tools: SM MZ. Wrote the paper: SM. Edited the paper: MZ. 29. Cook AL, Smith AG, Smit DJ, Leonard JH, Sturm RA (2005) Co-expression of SOX9 and SOX10 during melanocytic differentiation in vitro. Exp Cell Res 308: 222–235. 30. Venters SJ, Argent RE, Deegan FM, Perez-Baron G, Wong TS, et al. (2004) Precocious terminal differentiation of premigratory limb muscle precursor cells requires positive signalling. Dev Dyn 229: 591–599. 31. Ambler CA, Watt FM (2007) Expression of Notch pathway genes in mammalian epidermis and modulation by beta-catenin. Dev Dyn 236: 1595–1601. 32. Blanpain C, Lowry WE, Pasolli HA, Fuchs E (2006) Canonical notch signaling functions as a commitment switch in the epidermal lineage. Genes Dev 20: 3022–3035. 33. Krajewski S, Krajewska M, Shabaik A, Wang HG, Irie S, et al. (1994) Immunohistochemical analysis of in vivo patterns of Bcl-X expression. Cancer Res 54: 5501–5507. 34. Lehmann JM, Holzmann B, Breitbart EW, Schmiegelow P, Riethmuller G, et al. (1987) Discrimination between benign and malignant cells of melanocytic lineage by two novel antigens, a glycoprotein with a molecular weight of 113,000 and a protein with a molecular weight of 76,000. Cancer Res 47: 841–845. 35. Ohyama M, Terunuma A, Tock CL, Radonovich MF, Pise-Masison CA, et al. (2006) Characterization and isolation of stem cell-enriched human hair follicle bulge cells. J Clin Invest 116: 249–260. 36. Shih IM, Elder DE, Speicher D, Johnson JP, Herlyn M (1994) Isolation and functional characterization of the A32 melanoma-associated antigen. Cancer Res 54: 2514–2520. 37. Bardin N, Anfosso F, Masse JM, Cramer E, Sabatier F, et al. (2001) Identification of CD146 as a component of the endothelial junction involved in the control of cell-cell cohesion. Blood 98: 3677–3684. 38. Lyle S, Christofidou-Solomidou M, Liu Y, Elder DE, Albelda S, et al. (1998) The C8/144B monoclonal antibody recognizes cytokeratin 15 and defines the location of human hair follicle stem cells. J Cell Sci 111 (Pt 21): 3179–3188. 39. Nishimura EK, Jordan SA, Oshima H, Yoshida H, Osawa M, et al. (2002) Dominant role of the niche in melanocyte stem-cell fate determination. Nature 416: 854–860. 40. Osawa M, Egawa G, Mak SS, Moriyama M, Freter R, et al. (2005) Molecular characterization of melanocyte stem cells in their niche. Development 132: 5589–5599. 41. Yamamoto N, Tanigaki K, Han H, Hiai H, Honjo T (2003) Notch/RBP-J signaling regulates epidermis/hair fate determination of hair follicular stem cells. Curr Biol 13: 333–338. 42. Moriyama M, Osawa M, Mak SS, Ohtsuka T, Yamamoto N, et al. (2006) Notch signaling via Hes1 transcription factor maintains survival of melanoblasts and melanocyte stem cells. J Cell Biol 173: 333–339. 43. Aubin-Houzelstein G, Djian-Zaouche J, Bernex F, Gadin S, Delmas V, et al. (2008) Melanoblasts’ proper location and timed differentiation depend on Notch/RBP-J signaling in postnatal hair follicles. J Invest Dermatol 128: 2686–2695. 44. Barr FG, Galili N, Holick J, Biegel JA, Rovera G, et al. (1993) Rearrangement of the PAX3 paired box gene in the paediatric solid tumour alveolar rhabdomyosarcoma. Nat Genet 3: 113–117. 45. Bernasconi M, Remppis A, Fredericks WJ, Rauscher FJ, 3rd, Schafer BW (1996) Induction of apoptosis in rhabdomyosarcoma cells through down-regulation of PAX proteins. Proc Natl Acad Sci U S A 93: 13164–13169. 46. Borycki AG, Li J, Jin F, Emerson CP, Epstein JA (1999) Pax3 functions in cell survival and in pax7 regulation. Development 126: 1665–1674. 47. Galili N, Davis RJ, Fredericks WJ, Mukhopadhyay S, Rauscher FJ, 3rd, et al. (1993) Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 5: 230–235. 48. He SJ, Stevens G, Braithwaite AW, Eccles MR (2005) Transfection of melanoma cells with antisense PAX3 oligonucleotides additively complements cisplatin-induced cytotoxicity. Mol Cancer Ther 4: 996–1003. 49. Shapiro DN, Sublett JE, Li B, Downing JR, Naeve CW (1993) Fusion of PAX3 to a member of the forkhead family of transcription factors in human alveolar rhabdomyosarcoma. Cancer Res 53: 5108–5112. 50. Di Cristofano A, Pandolfi PP (2000) The multiple roles of PTEN in tumor suppression. Cell 100: 387–390. 51. Margue CM, Bernasconi M, Barr FG, Schafer BW (2000) Transcriptional modulation of the anti-apoptotic protein BCL-XL by the paired box transcription factors PAX3 and PAX3/FKHR. Oncogene 19: 2921–2929. 52. Leiter U, Schmid RM, Kaskel P, Peter RU, Krahn G (2000) Antiapoptotic bcl-2 and bcl-xL in advanced malignant melanoma. Arch Dermatol Res 292: 225–232. 53. Zhuang L, Lee CS, Scolyer RA, McCarthy SW, Zhang XD, et al. (2007) Mcl-1, Bcl-XL and Stat3 expression are associated with progression of melanoma PLoS ONE | www.plosone.org 10 April 2010 | Volume 5 | Issue 4 | e9977